Literature DB >> 3575097

The crystal structure of the DNA-binding drug berenil: molecular modelling studies of berenil-DNA complexes.

L H Pearl, J V Skelly, B D Hudson, S Neidle.   

Abstract

The crystal structure of the DNA minor-groove DNA-binding drug berenil has been determined. Molecular-modelling techniques have been used to establish plausible binding modes of the structure to A-T sequences. These have shown that specific hydrogen bonds are possible between the amidine groups of the drug molecule and 02 atoms of thymine, although global energy minimisations tended to emphasise electrostatic interactions with phosphate groups rather than these hydrogen bonds with bases.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3575097      PMCID: PMC340742          DOI: 10.1093/nar/15.8.3469

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  13 in total

Review 1.  Effects of the antibiotics netropsin and distamycin A on the structure and function of nucleic acids.

Authors:  C Zimmer
Journal:  Prog Nucleic Acid Res Mol Biol       Date:  1975

2.  Netropsin. A specific probe for A-T regions of duplex deoxyribonucleic acid.

Authors:  R M Wartell; J E Larson; R D Wells
Journal:  J Biol Chem       Date:  1974-11-10       Impact factor: 5.157

3.  Variation of the supercoils in closed circular DNA by binding of antibiotics and drugs: evidence for molecular models involving intercalation.

Authors:  M Waring
Journal:  J Mol Biol       Date:  1970-12-14       Impact factor: 5.469

4.  The solvation contribution to the binding energy of DNA with non-intercalating antibiotics.

Authors:  K Zakrzewska; R Lavery; B Pullman
Journal:  Nucleic Acids Res       Date:  1984-08-24       Impact factor: 16.971

5.  Existence of an extended series of antitumor compounds which bind to deoxyribonucleic acid by nonintercalative means.

Authors:  A W Braithwaite; B C Baguley
Journal:  Biochemistry       Date:  1980-03-18       Impact factor: 3.162

6.  A theoretical study of the nonintercalative binding of berenil and stilbamidine to double-stranded (dA-dT)n oligomers.

Authors:  N Gresh; B Pullman
Journal:  Mol Pharmacol       Date:  1984-05       Impact factor: 4.436

Review 7.  Phthalanilides and some related dibasic and polybasic compounds: a review of biological activities and modes of action.

Authors:  L L Bennett
Journal:  Prog Exp Tumor Res       Date:  1965

Review 8.  Nonintercalative DNA-binding antitumour compounds.

Authors:  B C Baguley
Journal:  Mol Cell Biochem       Date:  1982-04-02       Impact factor: 3.396

9.  Heteronomous DNA.

Authors:  S Arnott; R Chandrasekaran; I H Hall; L C Puigjaner
Journal:  Nucleic Acids Res       Date:  1983-06-25       Impact factor: 16.971

10.  Binding of an antitumor drug to DNA, Netropsin and C-G-C-G-A-A-T-T-BrC-G-C-G.

Authors:  M L Kopka; C Yoon; D Goodsell; P Pjura; R E Dickerson
Journal:  J Mol Biol       Date:  1985-06-25       Impact factor: 5.469

View more
  4 in total

1.  Interaction of berenil with the tyrT DNA sequence studied by footprinting and molecular modelling. Implications for the design of sequence-specific DNA recognition agents.

Authors:  C A Laughton; T C Jenkins; K R Fox; S Neidle
Journal:  Nucleic Acids Res       Date:  1990-08-11       Impact factor: 16.971

2.  A theoretical investigation of the base sequence preferences of monointercalating polymethylene carboxamide derivatives 9-aminoacridine.

Authors:  C Coulombeau; N Gresh
Journal:  Nucleic Acids Res       Date:  1990-02-25       Impact factor: 16.971

3.  DNA sequence preferences of several AT-selective minor groove binding ligands.

Authors:  A Abu-Daya; P M Brown; K R Fox
Journal:  Nucleic Acids Res       Date:  1995-09-11       Impact factor: 16.971

4.  Crystal structure of a berenil-dodecanucleotide complex: the role of water in sequence-specific ligand binding.

Authors:  D G Brown; M R Sanderson; J V Skelly; T C Jenkins; T Brown; E Garman; D I Stuart; S Neidle
Journal:  EMBO J       Date:  1990-04       Impact factor: 11.598

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.